NSI-189 is an experimental small molecule that helps your brain grow new neurons in the hippocampus, the region tied to memory, learning, and mood. It's the only compound currently being studied that does this directly, rather than as a side effect of changing serotonin or dopamine. People take it for stubborn low mood, brain fog, memory issues, or to recover cognitive function after stress, burnout, or long periods of poor sleep.
NSI-189 crosses the bloo-brain-barrier to directly modify gene expression in neurons. reduces neuronal apoptosis (cell death), increases neuroprotective protein synthesis
It was originally developed as a depression drug. The Phase 2 trial missed its primary endpoint, but patients consistently rated themselves as feeling better and thinking more clearly, and those benefits often held for weeks after stopping. That gap between what doctors measured and what patients reported is part of why NSI-189 is interesting, it seems to do something structurally to the brain that builds slowly and lingers, rather than masking symptoms while you're on it.
Deep-dive
NSI-189 (chemical name (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone) is a benzylpiperazine-aminopyridine developed by Neuralstem, sold to Alto Neuroscience in 2021, and now developed under the names ALTO-100 and amdiglurax. It's a hippocampal neurogenesis stimulant and indirect BDNF modulator, meaning it doesn't bind monoamine receptors at all. Its exact molecular target is still unknown.
How it actually works. The hippocampus is one of the only adult brain regions that grows new neurons throughout life, in a zone called the subgranular zone. Stress, depression, chronic high cortisol, sleep deprivation, and aging all suppress this process and shrink hippocampal volume. NSI-189 stimulates the proliferation and differentiation of neural stem cells in this zone. In animal work it enhances long-term potentiation (the cellular basis of learning), increases dendritic spine density, and at sufficient doses increases hippocampal volume by 15-20% in rodents.
Mechanistically, the compound enhances BDNF signaling indirectly rather than activating BDNF receptors itself. It also influences the mTOR pathway and modulates neuroinflammation. The fact that the precise target hasn't been identified after more than a decade of research is genuinely a limitation, we know what it does (neurogenesis, synaptic plasticity, mood and cognitive benefits in some patients) but not exactly how at the receptor level.
What the human data actually shows. The Phase 1B trial in 24 MDD patients (Fava et al., 2016) showed medium-to-large effect sizes across depression and cognitive measures, with benefits sustained 8 weeks after stopping the drug. This is unusual and was the original reason for excitement.
The larger Phase 2 trial in 220 outpatients (Papakostas et al., 2019) was less clean. Neither 40 mg nor 80 mg beat placebo on the primary clinician-rated MADRS scale. But on patient-rated scales, 40 mg significantly outperformed placebo on the Symptoms of Depression Questionnaire (Cohen's d = -0.64 in stage 2), the Cognitive and Physical Functioning Scale (d = -0.47), and the QIDS-SR (d = -0.68). On objective cognitive testing, 40 mg also showed advantages on the CogScreen battery. A post-hoc analysis found the strongest benefit in moderately depressed patients (MADRS < 30), not severely depressed ones.
The hippocampal volume increase that animal studies showed at high doses did not replicate significantly in the human Phase 2 trial. This is an important caveat, the structural change that's the headline mechanism in mice has not been clearly demonstrated in humans at the doses tested.
Beyond depression. Animal data suggests NSI-189 may help in stroke recovery, diabetic neuropathy, radiation-induced cognitive impairment, and Angelman syndrome. None of these have meaningful human trial data yet. Alto Neuroscience is currently running trials for MDD, bipolar depression, and PTSD.
Women. NSI-189 trials enrolled both sexes. Pharmacokinetics didn't differ between men and women in the Phase 1B study, meaning the same dose produces similar blood levels regardless of sex. There's no published evidence of sex-specific efficacy differences, but trials weren't powered to detect them. Two practical points worth knowing, women have a roughly 2x higher lifetime rate of depression and tend to show more pronounced hippocampal volume reduction with chronic stress and depression, so the structural target is, if anything, more relevant. Hormonal cycling affects baseline neurogenesis (oestrogen is pro-neurogenic) but no studies have looked at whether NSI-189 effects vary across the menstrual cycle. Pregnant and breastfeeding women were excluded from all trials and there's zero safety data for that population.
Older adults. All clinical trials excluded people over 60. This is a meaningful gap, because age-related hippocampal atrophy is exactly the kind of problem NSI-189 was designed to address. Whether it works as well, or at all, in someone in their 70s with significant volume loss is unknown. The compound is being explored for Alzheimer's preclinically but no human data exists.
Limitations of the evidence. The primary endpoint failed in the only large RCT. The patient-reported benefits are real but the gap between subjective and clinician-rated outcomes raises legitimate questions about expectancy effects, even with placebo control. Long-term safety data beyond 12 weeks is essentially nonexistent. The compound is not approved by any regulator. Most underground use relies on research-grade powder of variable purity.
Dosage:
- Standard dose: 20-40 mg once daily, taken in the morning. This is the dose with the most positive human data
- Higher dose: 80 mg per day (40 mg twice daily) was tested in Phase 2 but did not outperform 40 mg, suggesting the dose-response is flat or inverted above 40 mg for mood and cognition. More isn't better here
- Half-life is 17-20 hours, so once-daily dosing maintains steady levels. Splitting into 20 mg twice daily is reasonable for people sensitive to stimulating effects.
- Cycled 10-20 days on with 2-4 weeks off.
- Take with or without food. A Phase 1a study showed food does not meaningfully affect absorption
- Phosphate vs freebase: The phosphate salt is more water-soluble and is the form used in all clinical trials. Freebase requires a fat carrier for absorption
Here's what you can expect:
In the first week or two, the most commonly reported subjective change is a feeling of mental clarity, easier word recall, and reduced fog. Some people also notice improved focus and a slight lift in motivation. These early effects are subtle, not stimulant-like.
Mood improvements take longer, typically 3-4 weeks to become noticeable, and tend to feel like a baseline reset rather than a buzz. People describe feeling more like themselves rather than feeling artificially elevated. This matches the patient-reported data from clinical trials, where SDQ scores improved gradually over 12 weeks.
The compound is not a cognitive stimulant. It will not feel like caffeine, modafinil, or a racetam. If you're expecting acute cognitive enhancement you'll likely be disappointed. The mechanism is structural and slow.
Effects often persist after stopping. In the Phase 1B trial, improvements in depression scores held steady for 8 weeks post-treatment. This is consistent with a compound that's promoting actual structural changes rather than transient receptor effects.
Non-responders are real. The Phase 2 trial showed that benefits were strongest in moderately depressed patients and weaker in severely depressed ones. People with no baseline cognitive or mood issues may not notice much at all, which is consistent with how a neurogenesis-promoting compound would work, if your hippocampus isn't compromised, there's less to restore.
Side effects & risks:
- Most common: headache, dizziness, and mild somnolence. These were the dominant adverse events across all trials and were generally mild and self-limiting
- No serious adverse events were reported in any of the published Phase 1, 1B, or 2 trials. Discontinuation due to side effects was actually higher in the placebo group than the 40 mg group in Phase 2
- No physical dependence has been reported. The compound does not bind to receptors involved in addiction pathways
- Activation effects: A subset of users report increased anxiety or restlessness in the first 1-2 weeks. This typically settles. If it doesn't, the compound is probably not for you
- Sleep: Most users tolerate it fine in the morning. Late-day dosing can cause insomnia in sensitive people due to its long half-life
- GI: Mild nausea has been occasionally reported, usually resolved by taking with food
- Drug interactions: Not formally studied. The compound is metabolized hepatically, so concurrent use with strong CYP inhibitors or inducers is theoretically risky but unquantified. People on SSRIs, SNRIs, or MAOIs should be cautious, trials excluded patients on other antidepressants, so the combination has no safety data
- Long-term unknowns: Beyond 12 weeks there is no human safety data. Whether continuous neurogenesis stimulation has long-term consequences (such as effects on neural stem cell pool depletion) is theoretically possible but unstudiedw
NSI-189 is an investigational compound that has not been approved for medical use by any regulator.
Made with Bullet